EMEA-001214-PIP02-17
Key facts
| Active substance |
Benralizumab
|
| Therapeutic area |
Oto-rhino-laryngology
|
| Decision number |
P/0288/2017
|
| PIP number |
EMEA-001214-PIP02-17
|
| Pharmaceutical form(s) |
Solution for injection in pre-filled syringe
|
| Condition(s) / indication(s) |
Treatment of nasal polyposis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
AstraZeneca AB (Sweden)
Tel. +46 8 5532791 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|